Development and Validation of the Short Form of a Urinary Quality of Life Questionnaire: SF-Qualiveen

被引:106
作者
Bonniaud, Veronique [1 ,2 ]
Bryant, Dianne [1 ,3 ]
Parratte, Bernard [2 ]
Guyatt, Gordon [1 ]
机构
[1] McMaster Univ, Fac Hlth Sci, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada
[2] CHU Besancon, Serv Med Phys & Readaptat, F-25030 Besancon, France
[3] Univ Western Ontario, Sch Phys Therapy, London, ON, Canada
关键词
urinary bladder; neurogenic; multiple sclerosis; quality of life; questionnaires; urination disorders;
D O I
10.1016/j.juro.2008.08.016
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The 30-item Qualiveen is a specific health related quality of life questionnaire for urinary disorders in patients with neurological conditions, such as multiple sclerosis and spinal cord injury. Previous studies have demonstrated the reliability, validity and responsiveness of Qualiveen. However, to address the needs of large clinical trials and long-term monitoring, in which efficiency may compete with precision of measurement, we developed the 8-item self-administered SF-Qualiveen. Materials and Methods: A total of 180 English speaking and French speaking outpatients with multiple sclerosis at multiple sclerosis clinics and departments of rehabilitation in Canada and France completed the entire Qualiveen, the Multiple Sclerosis Quality of Life-54 questionnaire or its French version (SEP-59) as well as urinary function assessments at study enrollment and 2 to 10 weeks later. At visit 2 patients also made global ratings of change in urinary health related quality of life. SF-Qualiveen development and testing used this data set. Results: Correlations of SF-Qualiveen with its original form were high (r = 0.70 to 0.92). SF-Qualiveen proved reliable (ICC 0.83 to 0.93). Its responsiveness was similar to that of the long form (SRM 0.75 to 1.62). Correlations with other measures were consistent with our a priori predictions (weighted kappa 0.55 for cross-sectional correlations and 0.66 for correlations of change), supporting the cross-sectional and longitudinal construct validity of SF-Qualiveen. Conclusions: SF-Qualiveen has excellent measurement properties, similar to those of the long form. The new instrument is likely to perform well in the clinical and research context.
引用
收藏
页码:2592 / 2598
页数:7
相关论文
共 19 条
[1]   Quality of life in multiple sclerosis patients with urinary disorders: Discriminative validation of the English version of Qualiveen [J].
Bonniaud, V ;
Jackowski, D ;
Parratte, B ;
Paulseth, R ;
Grad, S ;
Margetts, P ;
Guyatt, G .
QUALITY OF LIFE RESEARCH, 2005, 14 (02) :425-431
[2]   Qualiveen, a urinary-disorder specific instrument: 0.5 corresponds to the minimal important difference [J].
Bonniaud, Veronique ;
Bryant, Dianne ;
Parratte, Bernard ;
Guyatt, Gordon .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2008, 61 (05) :505-510
[3]   Qualiveen: A urinary disorder - Specific instrument for use in clinical trials in multiple sclerosis [J].
Bonniaud, Veronique ;
Bryant, Dianne ;
Parratte, Bernard ;
Gallien, Philippe ;
Guyatt, Gordon .
ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 2006, 87 (12) :1661-1663
[5]   Quality of life in spinal cord injury patients with urinary difficulties - Development and validation of qualiveen [J].
Costa, P ;
Perrouin-Verbe, B ;
Colvez, A ;
Didier, JP ;
Marquis, P ;
Marrel, A ;
Amarenco, G ;
Espirac, B ;
Leriche, A .
EUROPEAN UROLOGY, 2001, 39 (01) :107-113
[6]   Methodological approaches to shortening composite measurement scales [J].
Coste, J ;
Guillemin, F ;
Pouchot, J ;
Fermanian, J .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1997, 50 (03) :247-252
[7]   Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q [J].
Coyne, K ;
Revicki, D ;
Hunt, T ;
Corey, R ;
Stewart, W ;
Bentkover, J ;
Kurth, H ;
Abrams, P .
QUALITY OF LIFE RESEARCH, 2002, 11 (06) :563-574
[8]  
Donovan JL, 2002, INCONTINENCE, 2ND EDITION, P267
[9]  
Fayers PM, 1997, QUAL LIFE RES, V6, P139
[10]   MEASUREMENT OF HEALTH-STATUS - ASCERTAINING THE MINIMAL CLINICALLY IMPORTANT DIFFERENCE [J].
JAESCHKE, R ;
SINGER, J ;
GUYATT, GH .
CONTROLLED CLINICAL TRIALS, 1989, 10 (04) :407-415